{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=29",
    "query": {
      "intervention": "Single intravenous doses of placebo",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 677,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+intravenous+doses+of+placebo&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T15:43:23.737Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04376684",
      "title": "Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Acute Respiratory Syndrome"
      ],
      "interventions": [
        {
          "name": "Otilimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard of care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1156,
      "start_date": "2020-05-28",
      "completion_date": "2021-08-16",
      "has_results": true,
      "last_update_posted_date": "2024-09-23",
      "last_synced_at": "2026-10-19T15:43:23.737Z",
      "location_count": 21,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04376684"
    },
    {
      "nct_id": "NCT04619420",
      "title": "A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Cognitive Dysfunction",
        "Dementia"
      ],
      "interventions": [
        {
          "name": "JNJ-63733657",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "55 Years to 80 Years"
      },
      "enrollment_count": 523,
      "start_date": "2021-01-06",
      "completion_date": "2026-03-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-10-19T15:43:23.737Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 47 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04619420"
    },
    {
      "nct_id": "NCT04545060",
      "title": "VIR-7831 for the Early Treatment of COVID-19 in Outpatients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "VIR-7831 (sotrovimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1057,
      "start_date": "2020-08-27",
      "completion_date": "2021-09-02",
      "has_results": true,
      "last_update_posted_date": "2022-11-07",
      "last_synced_at": "2026-10-19T15:43:23.737Z",
      "location_count": 63,
      "location_summary": "Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04545060"
    },
    {
      "nct_id": "NCT02516904",
      "title": "A Single Ascending Dose Study of CD101 IV in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "CD101 IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2015-07",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2024-05-22",
      "last_synced_at": "2026-10-19T15:43:23.737Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02516904"
    },
    {
      "nct_id": "NCT01287793",
      "title": "Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "tigecycline",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "100 mL 0.9% Sodium Chloride intravenous",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2011-01",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2011-05-24",
      "last_synced_at": "2026-10-19T15:43:23.737Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01287793"
    },
    {
      "nct_id": "NCT00822900",
      "title": "Progesterone for the Treatment of Traumatic Brain Injury III",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Traumatic Brain Injury"
      ],
      "interventions": [
        {
          "name": "Progesterone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Wright",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 882,
      "start_date": "2010-03",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2016-01-20",
      "last_synced_at": "2026-10-19T15:43:23.737Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tuscon, Arizona + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00822900"
    },
    {
      "nct_id": "NCT05670730",
      "title": "Study of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 Skipping",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy",
        "Exon 44"
      ],
      "interventions": [
        {
          "name": "AOC 1044",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "7 Years to 55 Years · Male only"
      },
      "enrollment_count": 70,
      "start_date": "2022-11-09",
      "completion_date": "2024-11-25",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-10-19T15:43:23.737Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • La Jolla, California • Palo Alto, California + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05670730"
    },
    {
      "nct_id": "NCT07449572",
      "title": "Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "ARDS (Acute Respiratory Distress Syndrome)"
      ],
      "interventions": [
        {
          "name": "HT31-1",
          "type": "DRUG"
        },
        {
          "name": "Saline (0.9%, sterile, for infusion)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "HTIC, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-05-28",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-19T15:43:23.737Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07449572"
    },
    {
      "nct_id": "NCT04173819",
      "title": "Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "3BNC117-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "10-1074-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 225,
      "start_date": "2019-01-25",
      "completion_date": "2023-09-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-06",
      "last_synced_at": "2026-10-19T15:43:23.737Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • New York, New York • Seattle, Washington",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04173819"
    },
    {
      "nct_id": "NCT06967259",
      "title": "ENA-001 for Opioid Induced Respiratory Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Depression"
      ],
      "interventions": [
        {
          "name": "ENA-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enalare Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 62,
      "start_date": "2025-05-14",
      "completion_date": "2026-08-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-19T15:43:23.737Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Overland Park, Kansas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06967259"
    }
  ]
}